Your browser is no longer supported. Please, upgrade your browser.
Settings
ARNA [NASD]
Arena Pharmaceuticals, Inc.
Index- P/E- EPS (ttm)-0.28 Insider Own0.60% Shs Outstand241.45M Perf Week-9.79%
Market Cap1.05B Forward P/E- EPS next Y-0.36 Insider Trans-10.22% Shs Float240.10M Perf Month-8.84%
Income-60.50M PEG- EPS next Q-0.14 Inst Own48.50% Short Float14.27% Perf Quarter21.29%
Sales37.00M P/S28.26 EPS this Y-211.10% Inst Trans7.43% Short Ratio3.77 Perf Half Y4.84%
Book/sh0.21 P/B20.62 EPS next Y32.10% ROA-19.00% Target Price7.58 Perf Year-31.27%
Cash/sh0.68 P/C6.41 EPS next 5Y- ROE-68.80% 52W Range3.26 - 7.22 Perf YTD24.78%
Dividend- P/FCF- EPS past 5Y31.20% ROI-89.20% 52W High-40.03% Beta-0.52
Dividend %- Quick Ratio2.50 Sales past 5Y28.90% Gross Margin78.90% 52W Low32.82% ATR0.26
Employees325 Current Ratio2.70 Sales Q/Q41.50% Oper. Margin- RSI (14)42.37 Volatility5.45% 5.95%
OptionableYes Debt/Eq1.49 EPS Q/Q-36.40% Profit Margin- Rel Volume0.30 Prev Close4.34
ShortableYes LT Debt/Eq1.44 EarningsMar 02 AMC Payout- Avg Volume9.08M Price4.33
Recom2.70 SMA20-4.59% SMA50-6.34% SMA200-3.90% Volume2,684,092 Change-0.23%
Jan-23-15Initiated RBC Capital Mkts Sector Perform $5
Aug-07-14Reiterated WallachBeth Buy $9 → $8
Nov-15-13Initiated WallachBeth Buy $9
Oct-03-13Initiated Cowen Market Perform $4.50
Oct-25-10Reiterated Barclays Capital Underweight $3 → $2
Sep-20-10Reiterated UBS Neutral $7 → $2
Sep-17-10Downgrade Davenport Buy → Neutral
Sep-14-10Downgrade Barclays Capital Equal Weight → Underweight $4 → $3
Aug-23-10Reiterated UBS Neutral $3.50 → $7
Jul-16-10Downgrade Rodman & Renshaw Mkt Perform → Mkt Underperform $1
Jul-02-10Reiterated UBS Buy $40 → $38
Feb-04-10Upgrade Rodman & Renshaw Mkt Underperform → Mkt Perform
Dec-17-09Initiated Jefferies & Co Hold $4
Sep-21-09Downgrade Leerink Swann Outperform → Mkt Perform $6
Sep-18-09Downgrade Rodman & Renshaw Mkt Perform → Mkt Underperform $3
Sep-15-09Downgrade Rodman & Renshaw Mkt Outperform → Mkt Perform
Aug-18-09Initiated JMP Securities Mkt Perform
Jun-24-09Initiated Rodman & Renshaw Mkt Outperform $9
Mar-16-09Downgrade Canaccord Adams Hold → Sell
Feb-18-09Downgrade UBS Buy → Neutral $6 → $7
Mar-27-15 08:25AM  Ahead of the Bell: Orexigen shares rise
Mar-19-15 09:30AM  Zacks Rank #5 Additions for Thursday - Tale of the Tape
Mar-11-15 09:30AM  Zacks Rank #5 Additions for Wednesday - Tale of the Tape
Mar-10-15 01:04PM  ARENA PHARMACEUTICALS INC Financials +6.37%
Mar-09-15 05:06PM  Novo Nordisk's Saxenda: New Data from Phase IIIa Study - Analyst Blog
Mar-07-15 12:40AM  Arena Pharmaceuticals Provides Corporate Update and Reports Fourth Quarter and Full Year 2014 Financial Results at noodls
Mar-05-15 11:20PM  Is Arena Pharmaceuticals In Trouble? at Investopedia
Mar-04-15 07:09PM  10-K for Arena Pharmaceuticals, Inc. at Company Spotlight +6.93%
11:35AM  Biotech Stock Roundup: Orexigen Soars on Contrave Data, Amgen Scores in Study - Analyst Blog
09:34AM  Arena Pharmaceuticals Announces Fourth Quarter and Full Year 2014 Financial Results Conference Call and Webcast on Monday, March 2 at noodls
Mar-03-15 04:26PM  ARENA PHARMACEUTICALS INC Files SEC form 8-K, Regulation FD Disclosure -5.61%
01:54PM  Orexigen Soars On Obesity Drug's Surprise Health Boon at Investor's Business Daily
11:51AM  Orexigen Weight-Loss Pill Shows Surprise Heart-Safety Benefit at TheStreet
10:28AM  Arena Pharmaceuticals' Q4 Loss Wider than Expected - Analyst Blog Zacks
Mar-02-15 06:45PM  Arena Pharmaceuticals Misses Q4 Expectations Benzinga -5.10%
05:14PM  Arena Pharmaceuticals reports 4Q loss AP
04:01PM  Arena Pharmaceuticals Provides Corporate Update and Reports Fourth Quarter and Full Year 2014 Financial Results PR Newswire
Feb-27-15 04:22PM  Will Arena Pharmaceuticals (ARNA) Disappoint on Q4 Earnings? - Analyst Blog Zacks -5.05%
Feb-23-15 08:00AM  Arena Pharmaceuticals Announces Fourth Quarter and Full Year 2014 Financial Results Conference Call and Webcast on Monday, March 2 PR Newswire
Feb-20-15 03:47PM  Obesity Drugs: Orexigen Gains Market Share at Expense of Arena, Vivus at TheStreet -5.10%
Feb-18-15 08:00AM  Arena Pharmaceuticals to Present at the 2015 RBC Capital Markets Healthcare Conference PR Newswire
06:38AM  A Vue cinema will become the UK's first eSports arena next month at Engadget
Feb-17-15 09:06AM  Arena's Broader Product Footprint Drives Q4 Growth Of 38 Percent CNW Group
Feb-03-15 10:00AM  Eforb: From Indie Game Development to Monetization and Distribution Platform CNW Group
08:46AM  ARENA PHARMACEUTICALS INC Files SEC form 8-K, Other Events EDGAR Online
05:00AM  Arena Pharmaceuticals Announces Marketing Approval in South Korea of BELVIQ® (lorcaserin HCl) for Weight Management PR Newswire
Feb-02-15 08:00AM  Arena Pharmaceuticals to Present at the 17th Annual BIO CEO & Investor Conference PR Newswire
Jan-29-15 08:54AM  An Early Version Of Samsung's Next Galaxy Phone Might Have Just Leaked Business Insider
Jan-23-15 04:52PM  ARENA PHARMACEUTICALS INC Files SEC form 8-K, Other Events, Financial Statements and Exhibits EDGAR Online
11:49AM  Brazil's $3 Billion World Cup Stadiums Are Turning Into White Elephants 6 Months Later Business Insider
06:18AM  Coverage initiated on Arena Pharm by RBC Capital Mkts Briefing.com
06:00AM  Biotech Stock Mailbag: Arena Pharma, Agenus, EnteroMedics at TheStreet
Jan-22-15 04:00PM  Arena Pharmaceuticals to Raise Fund Via Share Issuance - Analyst Blog Zacks
Jan-21-15 05:45PM  Stock Pops & Drops: CHL, ARNA, MBLY & ANTM CNBC -10.96%
03:10PM  Mid-Afternoon Market Update: Alnylam Pharmaceuticals Drops Following Equity Offering; Insperity Shares Spike Higher Benzinga
10:42AM  Mid-Morning Market Update: Markets Mixed; UnitedHealth Profit Tops Expectations Benzinga
08:45AM  Arena Pharmaceuticals Announces Agreement to Sell Common Stock Benzinga
08:45AM  Arena Pharmaceuticals Announces Agreement to Sell Common Stock PR Newswire
Jan-20-15 05:16PM  ARENA PHARMACEUTICALS INC Files SEC form 8-K, Results of Operations and Financial Condition, Other Events EDGAR Online
04:04PM  Arena Pharmaceuticals Announces Public Offering of Common Stock PR Newswire
12:34PM  Did you know Arena Pharmaceuticals is a CAR-T company? Neither did I. Next week, it will be gene therapy. I guess anything is better than being known for peddling a mediocre weight loss pill with disappointing fourth-quarter sales . Yahoo Finance Contributors
Jan-16-15 02:20PM  Arena Pharmaceuticals Doses for Cardiovascular Study - Analyst Blog Zacks
Jan-15-15 09:57AM  Can the Uptrend Continue for Arena Pharma (ARNA)? - Tale of the Tape Zacks -8.29%
Jan-14-15 01:55PM  5 Obesity Stocks Investors Are Watching Benzinga -6.28%
09:00AM  Indie Game Developer Eforb Launches Game Publishing Service: Gamebox Arena CNW Group
Jan-12-15 04:21PM  ARENA PHARMACEUTICALS INC Files SEC form 8-K, Other Events EDGAR Online
08:00AM  Arena Pharmaceuticals Initiates Phase 2 Clinical Trial Evaluating Ralinepag for Pulmonary Arterial Hypertension PR Newswire
Jan-09-15 08:00AM  Arena Pharmaceuticals Reports on Eisai's New Marketing Initiatives for BELVIQ® (lorcaserin HCl) CIV PR Newswire -5.73%
07:32AM  ARENA PHARMACEUTICALS INC Files SEC form 8-K, Other Events EDGAR Online
Jan-07-15 01:00PM  Midday movers: Alkermes, Lennar, Radian Group & more at CNBC +76.20%
12:30PM  Arena Pharma surges on data from autoimmune drug study AP
08:00AM  Arena Pharmaceuticals Reports Positive Results from Phase 1b Clinical Trial Evaluating APD334 for the Treatment of Autoimmune Diseases PR Newswire
Jan-06-15 08:00AM  Arena Pharmaceuticals to Present at the 33rd Annual J.P. Morgan Healthcare Conference PR Newswire -5.68%
Dec-23-14 04:49PM  FDA clears Novo Nordisk's weight loss drug Saxenda AP -5.79%
Dec-19-14 02:09PM  Orexigen Therapeutics Gains On Diet Pill Nod From European Committee Benzinga
Dec-12-14 11:58AM  Obesity Pill Upstart Orexigen Therapeutics Gaining on Rivals Yahoo Finance Blogs
Dec-05-14 05:26PM  ARENA PHARMACEUTICALS INC Files SEC form 8-K, Regulation FD Disclosure EDGAR Online
Nov-25-14 08:00AM  Arena Pharmaceuticals Issued Composition of Matter Patent by United States Patent and Trademark Office for Ralinepag and Related Compounds PR Newswire
Nov-24-14 08:00AM  Arena Pharmaceuticals to Present at Piper Jaffray 26th Annual Healthcare Conference PR Newswire
Nov-13-14 12:10PM  What's Driving Orexigen Therapeutics Higher? Benzinga
08:00AM  Arena Pharmaceuticals to Present at Stifel 2014 Healthcare Conference PR Newswire
06:28AM  Arena Pharmaceuticals (ARNA) Shares March Higher, Can It Continue? Zacks
Nov-08-14 07:07PM  10-Q for Arena Pharmaceuticals, Inc. Company Spotlight
Nov-06-14 04:57PM  ARENA PHARMACEUTICALS INC Files SEC form 10-Q, Quarterly Report EDGAR Online
08:00AM  Lorcaserin HCl Data to be Presented at the Annual Meeting of the American Association for the Study of Liver Diseases PR Newswire
Nov-05-14 08:00AM  Arena Pharmaceuticals to Present at Credit Suisse 2014 Healthcare Conference PR Newswire
Nov-04-14 08:30AM  Arena Pharmaceuticals Posts In Line Q3 Loss, Belviq Grows Zacks
Nov-03-14 02:40PM  Arena Pharma's 'Belviq' potential CNBC
08:37AM  Arena Pharmaceuticals Reports Q3 Loss, Shares Surge 6% Benzinga
07:31AM  ARENA PHARMACEUTICALS INC Files SEC form 8-K, Results of Operations and Financial Condition, Other Events, Financial EDGAR Online
07:27AM  Arena Pharmaceuticals tops 3Q profit forecasts AP
07:07AM  Q3 2014 Arena Pharmaceuticals Inc Earnings Release - Before Market Open CCBN
06:45AM  Arena Pharmaceuticals Provides Corporate Update and Reports Third Quarter 2014 Financial Results PR Newswire
06:30AM  Eisai and Arena Pharmaceuticals Report Results of an Investigational Phase 2 Trial of Lorcaserin HCl as an Aid for Smoking Cessation PR Newswire
Oct-31-14 03:20PM  Will Arena Pharma (ARNA) Q3 Loss Be Wider than Expected? Zacks
08:00AM  Lorcaserin Data to be Presented at The Obesity Society's Annual Scientific Meeting PR Newswire
06:40AM  Biotech Stock Mailbag: Prosensa, Sarepta, Arena Pharma, Hemispherx at TheStreet
Oct-30-14 09:19AM  ARENA PHARMACEUTICALS INC Files SEC form 8-K, Regulation FD Disclosure EDGAR Online
Oct-29-14 07:30AM  Arena Skimps on Data Disclosure From Weight-Loss Combo Study at TheStreet
Oct-28-14 06:20PM  Eisai and Arena Pharmaceuticals Report Results of an Investigational Pilot Study of Coadministration of Lorcaserin HCl and Phentermine HCl PR Newswire
Oct-27-14 08:00AM  Arena Pharmaceuticals Announces Third Quarter 2014 Conference Call and Webcast on Monday, November 3 PR Newswire
Oct-20-14 04:58PM  Bank Of America Q3 Small & Mid-Cap Biotech Preview Benzinga
Oct-13-14 08:00AM  Eisai and Arena Pharmaceuticals Announce Presentation of Lorcaserin HCl Data at the American College of Clinical Pharmacy Annual Meeting PR Newswire
Oct-10-14 11:36AM  Eisai and Arena Pharmaceuticals Announce Publication of Pooled Phase 3 Clinical Trial Analysis of BELVIQ® (lorcaserin HCl) CIV in Postgraduate Medicine PR Newswire
Oct-09-14 04:41PM  ARENA PHARMACEUTICALS INC Files SEC form 8-K, Amendments to Articles of Inc. or Bylaws; Change in Fiscal Year, Financ EDGAR Online
Oct-02-14 12:10PM  Zafgen Aims Obesity Drug At Rare, Deadly Disease at Forbes
Sep-30-14 10:37AM  [video] Zafgen CEO: 2015 Will Be Data Rich Year for Obesity Treatment at TheStreet
Sep-22-14 08:00AM  Arena Pharmaceuticals to Present at the NewsMakers in the Biotech Industry Conference PR Newswire
Sep-19-14 06:43AM  Arena Pharmaceuticals, Inc. (ARNA) Jumps: Stock Rises 9.5% Zacks
Sep-16-14 09:48AM  Doc Offers Glimpse Into Arena Pharma Weight-Loss Combination Therapy at TheStreet
Sep-11-14 05:15PM  [video] Orexigen drops in spite of FDA approval at CNBC
04:00PM  U.S. FDA panel: Novo Nordisk's liraglutide safe/effective for obesity Reuters
01:23PM  Orexigen's Obesity Pill is Approved and Stock Falls. Don't be Surprised at TheStreet
08:37AM  Pharmalot, Pharmalittle: We're Reading About Orexigen, Allergan and Lots More!! at The Wall Street Journal
07:18AM  FDA approves weight-loss drug Contrave AP
Sep-10-14 09:16PM  New Drug to Treat Obesity Gains Approval by F.D.A. at New York Times
07:58PM  FDA Approves Contrave Weight Loss Drug From Orexigen And Takeda at Forbes
07:00PM  Orexigen Wins U.S. FDA Approval for Weight-Loss Pill at Bloomberg
08:00AM  Lorcaserin HCl Data to be Presented at the American Society of Bariatric Physicians' 64th Annual Obesity & Associated Conditions Symposium PR Newswire
Sep-09-14 09:32AM  FDA staff: Novo Nordisk drug liraglutide effective for obesity Reuters
Arena Pharmaceuticals, Inc., a biopharmaceutical company, discovers, develops, and commercializes novel drugs that target G protein-coupled receptors. The company offers BELVIQ, a drug used to treat chronic weight management in adults. It is also developing a portfolio of programs in various therapeutic areas, including cardiovascular, central nervous system, and metabolic diseases. Its products under development include Ralinepag, an agonist of the prostacyclin receptor intended for the treatment of vascular diseases, including potentially pulmonary arterial hypertension that is in Phase II clinical trials. The company's products under development also comprise APD334, an modulator of the sphingosine 1-phosphate subtype 1 receptor for the treatment of a various autoimmune diseases, which has completed Phase I single-ascending dose trials; APD371, an agonist of the cannabinoid receptor 2 that is in Phase I clinical trials intended for the treatment of pain and fibrotic diseases; and Temanogrel, an inverse agonist of the serotonin 2A receptor intended for the treatment of thrombotic diseases, which has completed single- and multiple-ascending dose Phase I clinical trials. In addition it manufactures drug products under a toll manufacturing agreement for Siegfried AG. The company was founded in 1997 and is based in San Diego, California.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
SPECTOR STEVEN WEVP, General Counsel & SecMar 17Option Exercise1.5170,000105,803198,039Mar 18 05:45 PM
SPECTOR STEVEN WEVP, General Counsel & SecMar 17Sale5.0070,000350,000128,039Mar 18 05:45 PM
LIEF JACKPresident and CEOMar 03Option Exercise1.49125,000186,250622,189Mar 04 05:54 PM
SPECTOR STEVEN WEVP, General Counsel & SecJan 08Option Exercise6.1645,000277,200173,039Jan 08 09:08 PM
SPECTOR STEVEN WEVP, General Counsel & SecJan 08Sale6.2645,000281,700128,039Jan 08 09:08 PM
SHANAHAN WILLIAM R JRSVP & Chief Medical OfficerJan 07Option Exercise1.4950,00074,500100,000Jan 08 09:07 PM
SHANAHAN WILLIAM R JRSVP & Chief Medical OfficerJan 07Sale5.4950,000274,50050,000Jan 08 09:07 PM
LIEF JACKChairman, President and CEOSep 17Option Exercise1.49100,000149,000441,039Sep 19 04:50 PM
LIEF JACKChairman, President and CEOJul 01Sale5.85223,5251,308,582361,039Jul 03 04:38 PM
BELCHER DONALD DDirectorJun 27Option Exercise5.462,47313,50396,585Jun 27 06:49 PM
BELCHER DONALD DDirectorJun 27Sale5.852,47314,46794,112Jun 27 06:49 PM
SPECTOR STEVEN WEVP, General Counsel & SecMay 12Option Exercise1.4945,00067,050147,187May 14 07:34 PM
SPECTOR STEVEN WEVP, General Counsel & SecMay 12Sale7.0545,000317,358102,187May 14 07:34 PM
BELCHER DONALD DDirectorMay 06Option Exercise4.314,17617,99972,904May 07 07:54 PM
BELCHER DONALD DDirectorMay 06Sale7.004,17629,23268,728May 07 07:54 PM
HIXSON HARRY F JRDirectorApr 22Option Exercise4.1136,900151,659119,776Apr 24 06:14 PM
HIXSON HARRY F JRDirectorApr 22Sale6.3136,900232,75482,876Apr 24 06:14 PM
Nova Tina SusanDirectorApr 14Option Exercise4.7035,000164,35053,728Apr 15 09:59 PM
Nova Tina SusanDirectorApr 14Sale6.2235,000217,76318,728Apr 15 09:59 PM
BELCHER DONALD DDirectorApr 01Option Exercise6.301,90512,00270,633Apr 02 08:34 PM
SHANAHAN WILLIAM R JRSVP & Chief Medical OfficerApr 01Option Exercise6.3060,000378,00095,000Apr 02 08:35 PM
SHANAHAN WILLIAM R JRSVP & Chief Medical OfficerApr 01Sale6.3760,000382,01435,000Apr 02 08:35 PM
BELCHER DONALD DDirectorApr 01Sale6.451,90512,28768,728Apr 02 08:34 PM